Welcome to the Office of Cancer Survivorship Program, DCCPS
The NCI Office of Cancer Survivorship (OCS) works to enhance the quality and length of survival of all persons diagnosed with cancer and to prevent, minimize, or manage adverse effects of cancer and its treatment.
In this recent study in the Journal of Cancer Survivorship, OCS Deputy Director Dr. Michelle Mollica and co-authors conclude that survivorship objectives and strategies in Africa should extend beyond palliative care to encompass all aspects of survivorship, as well as include indicators to measure progress.
January 2023 – Join the Office of Cancer Survivorship for this webinar on January 31, 2023, from 2-3 p.m. ET. Dr. Charles Kamen will present The Rainbow Connection: Building a Career as an LGBTQ+ Scientist. OCS created the New Investigators Series to support those who are early in their career in cancer survivorship research. Register now for this upcoming event.
February 2023 – Register now for this upcoming OCS Director’s Series webinar. On February 28, 2023, from 3-4 p.m. ET, Dr. Ray Chan will present Innovations in Survivorship Models of Care.
March 2023 – Join the Office of Cancer Survivorship for this upcoming OCS Director’s Series webinar on March 21, 2023, from 2-3 p.m. ET. Dr. Stacy Loeb will present Cancer Information Online: Misinformation and Other Pitfalls for Cancer Survivors. Register now.
About The Office of Cancer Survivorship
An individual is considered a cancer survivor from the time of diagnosis, through the balance of life. There are many types of survivors, including those living with cancer and those free of cancer. This term is meant to capture a population of those with a history of cancer rather than to provide a label that may or may not resonate with individuals.
OCS works to promote a better understanding of unique needs of the growing population of cancer survivors, and to enhance our ability to address them.
Featured Graph and Statistic
Researchers at the National Cancer Institute have estimated that 623,405 people in the United States were living with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma as of 2018, and that number is expected to increase to 693,452 by the year 2025.